Rocio
Ferreiro Iglesias
Mutua de Terrassa
Terrassa, EspañaPublications in collaboration with researchers from Mutua de Terrassa (7)
2024
-
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)
Gastroenterologia y Hepatologia, Vol. 47, Núm. 8, pp. 821-833
-
Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU
Therapeutic Advances in Gastroenterology, Vol. 17
-
Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)
Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 750-758
-
Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study
Journal of Clinical Medicine, Vol. 13, Núm. 2
-
Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU
Digestive and Liver Disease
2022
-
The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study
Journal of Crohn's & colitis, Vol. 16, Núm. 11, pp. 1676-1686